Positron Emission Tomography Imaging of Transplant Function

Overview

Journal NeuroRx

Specialty Neurology

Date 2005 Feb 18

PMID 15717049

Citations 4

Authors

David J Brooks

Affiliations

Soon will be listed here.

Abstract

In this article, the role of functional imaging for providing objective evidence that grafts of fetal tissue can survive and form connections in Parkinson's and Huntington's disease patients is reviewed. The dissociation between dopamine storage capacity, clinical improvement, and normalization of brain metabolism in PD is discussed, and possible mechanisms underlying the phenomenon of dyskinesias off medication are presented. It is concluded the positron emission tomography and single photon emission computed tomography can provide valuable ancillary information alongside clinical observations but are not currently appropriate modalities for use as surrogate endpoints.

Citing Articles

Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease.

Politis M BMC Med. 2011; 9:50.

PMID: 21569273 PMC: 3098794. DOI: 10.1186/1741-7015-9-50.

Pharmacological MRI (phMRI) monitoring of treatment in hemiparkinsonian rhesus monkeys.

Luan L, Ding F, Ai Y, Andersen A, Hardy P, Forman E Cell Transplant. 2008; 17(4):417-25.

PMID: 18522244 PMC: 2605704.

MR-based imaging of neural stem cells.

Politi L Neuroradiology. 2007; 49(6):523-34.

PMID: 17345076 DOI: 10.1007/s00234-007-0219-z.

Molecular imaging of cell transplantation in Parkinson's disease.

Vander Borght T Eur J Nucl Med Mol Imaging. 2006; 33(4):403-6.

PMID: 16450137 DOI: 10.1007/s00259-005-0041-y.

References

Kordower J, Freeman T, Snow B, Vingerhoets F, Mufson E, Sanberg P . Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med. 1995; 332(17):1118-24. DOI: 10.1056/NEJM199504273321702. View

Laruelle M, Abi-Dargham A, van Dyck C, Rosenblatt W, Zea-Ponce Y, Zoghbi S . SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995; 36(7):1182-90. View

Turjanski N, Weeks R, Dolan R, Harding A, Brooks D . Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain. 1995; 118 ( Pt 3):689-96. DOI: 10.1093/brain/118.3.689. View

Jahanshahi M, Jenkins I, Brown R, Marsden C, Passingham R, Brooks D . Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. Brain. 1995; 118 ( Pt 4):913-33. DOI: 10.1093/brain/118.4.913. View

Freeman T, Olanow C, Hauser R, Nauert G, Smith D, Borlongan C . Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol. 1995; 38(3):379-88. DOI: 10.1002/ana.410380307. View

Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin J . Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol. 1995; 38(4):580-8. DOI: 10.1002/ana.410380406. View

Marek K, Seibyl J, Zoghbi S, Zea-Ponce Y, Baldwin R, Fussell B . [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996; 46(1):231-7. DOI: 10.1212/wnl.46.1.231. View

Torres E, Fricker R, Hume S, Myers R, Opacka-Juffry J, Ashworth S . Assessment of striatal graft viability in the rat in vivo using a small diameter PET scanner. Neuroreport. 1995; 6(15):2017-21. DOI: 10.1097/00001756-199510010-00016. View

Weeks R, Piccini P, Harding A, Brooks D . Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol. 1996; 40(1):49-54. DOI: 10.1002/ana.410400110. View

10.

Kordower J, Rosenstein J, Collier T, Burke M, Chen E, Li J . Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol. 1996; 370(2):203-30. DOI: 10.1002/(SICI)1096-9861(19960624)370:2<203::AID-CNE6>3.0.CO;2-6. View

11.

Vingerhoets F, Schulzer M, Calne D, Snow B . Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Ann Neurol. 1997; 41(1):58-64. DOI: 10.1002/ana.410410111. View

12.

Frey K, Koeppe R, Kilbourn M, Vander Borght T, Albin R, Gilman S . Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1996; 40(6):873-84. DOI: 10.1002/ana.410400609. View

13.

Antonini A, Leenders K, Spiegel R, Meier D, Vontobel P, Sanchez-Pernaute R . Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain. 1996; 119 ( Pt 6):2085-95. DOI: 10.1093/brain/119.6.2085. View

14.

Kuwert T, Lange H, Langen K, Herzog H, Aulich A, Feinendegen L . Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain. 1990; 113 ( Pt 5):1405-23. DOI: 10.1093/brain/113.5.1405. View

15.

Brooks D, Salmon E, Mathias C, Quinn N, Leenders K, Bannister R . The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain. 1990; 113 ( Pt 5):1539-52. DOI: 10.1093/brain/113.5.1539. View

16.

Grafton S, Mazziotta J, Pahl J, St George-Hyslop P, Haines J, Gusella J . A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol. 1990; 28(5):614-21. DOI: 10.1002/ana.410280503. View

17.

Brucke T, Podreka I, Angelberger P, Wenger S, Topitz A, Kufferle B . Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab. 1991; 11(2):220-8. DOI: 10.1038/jcbfm.1991.53. View

18.

Brooks D, Ibanez V, Sawle G, Playford E, Quinn N, Mathias C . Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol. 1992; 31(2):184-92. DOI: 10.1002/ana.410310209. View

19.

Playford E, Brooks D . In vivo and in vitro studies of the dopaminergic system in movement disorders. Cerebrovasc Brain Metab Rev. 1992; 4(2):144-71. View

20.

Playford E, Jenkins I, Passingham R, Nutt J, Frackowiak R, Brooks D . Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol. 1992; 32(2):151-61. DOI: 10.1002/ana.410320206. View